Day: March 8, 2026

– New analyses out to 24-months showed improvement in heart and lung function compared to expected declines in DMD natural history – – Data expand on previously reported results demonstrating that z-rostudirsen treatment led to sustained functional improvement across multiple clinical measures – WALTHAM, Mass., March 08, 2026 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced additional positive data from the ongoing Phase 1/2 DELIVER clinical trial of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251), in individuals with Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping. These data are being presented in a late-breaking poster...

– HARMONIA trial will assess multi-system efficacy, safety and tolerability of z-basivarsen in DM1 – – 48-week trial will enroll approximately 150 individuals, and first sites are now open for enrollment – – Primary endpoint is the five times sit to stand (5xSTS) test; secondary and exploratory endpoints will assess muscle function, CNS manifestations, and patient- and clinician-reported outcomes – – HARMONIA trial design and protocol aligned with FDA; trial intended to serve as confirmatory trial for traditional approval in the U.S. and support ex-U.S. marketing applications – WALTHAM, Mass., March 08, 2026 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular...

NEW YORK and WALTHAM, Mass., March 08, 2026 (GLOBE NEWSWIRE) — Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced a conference call and webcast to discuss the interim responder analysis results from Part A of the Phase 3 CAPTIVATE trial of claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) scheduled for tomorrow, Monday, March 9, 2026 at 8:00 a.m. ET. Investor Conference Call & Webcast InformationTo access the live conference call by phone, please register here. Conference call participants in the question and answer session should pre-register to receive the dial-in number and personal PIN.  The live webcast may be accessed via the Investors section...

VANCOUVER, British Columbia and BOSTON, March 08, 2026 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, will announce topline data from the Phase 3 X-TOLE2 study of azetukalner, a novel, potent KV7 potassium channel opener, in patients with focal onset seizures (FOS), on Monday, March 9, 2026.Conference Call/Webcast Information:   Date: Monday, March 9, 2026   Time: 8:00 am ET (5:00 am PT)   Webcast: Pre-register here   Dial-In: (800) 715-9871 toll-free or (646) 307-1963 for international callers   Conference ID: 7885306   A live webcast of the company presentation will be available on the Investors section...